Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Cited by (523)

Items 101–200 of 523

1. Cancer-nervous system crosstalk: from biological mechanism to therapeutic opportunities
   Sirui Huang, Jing Zhu, Linglu Yu, Yan Huang, Yue Hua Hu · 2025 · Molecular Cancer
2. NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
   Yuekun Wang, Piaopiao Long, Yu Wang, Wenbin Ma · 2020 · Frontiers in Oncology
3. Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
   Xiaoling Song, Hui Zhong, Xiaojuan Qu, Linsong Yang, Biao Jiang · 2021 · MedComm
4. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer
   Wook Jin · 2020 · Cancers
5. Targeted Therapies in Cancer: To Be or Not to Be, Selective
   Skye Montoya, Deborah Soong, Nina Thuha Nguyen, Maurizio Affer, Sailasya P. Munamarty, Justin Taylor · 2021 · Biomedicines
6. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation
   Linsheng Zhuo, Mingshu Wang, Fengxu Wu, Hong-Chuang Xu, Yi Gong, Zhi‐Cheng Yu, Yan-Guang Tian, Chao Pang, Ge‐Fei Hao, Wei Huang et al. · 2021 · Journal of Medicinal Chemistry
7. Overcoming cancer therapy resistance: From drug innovation to therapeutics
   Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, Joshua S. Fleishman, Hui Juan Yu, Xiao-Li Chen, Xiang-Tu Kong, Shan‐Liang Sun, Nian‐Guang Li, Ye Yang et al. · 2025 · Drug Resistance Updates
8. ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
   Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuanyuan Chen, Na Li, Xiaochun Peng, Jun Cai, Zhi-Qiang Cai · 2022 · Journal of drug targeting
9. Synthesis and clinical application of new drugs approved by FDA in 2023
   Yatao Wang, Pengcheng Yang, Yanfeng Zhang, Jinfeng Sun · 2024 · European Journal of Medicinal Chemistry
10. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
    Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett · 2021 · Journal of Medicinal Chemistry
11. Precision Oncology: 2023 in Review
    Yonina R. Murciano‐Goroff, Sarah Phillips Suehnholz, Alexander Edward Dela Cruz Drilon, Debyani Chakravarty · 2023 · Cancer Discovery
12. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
    Cinta Hierro, Ignacio Garcia Matos, Juan Martín-Liberal, María Ochoa de Olza, Elena Garralda · 2019 · Clinical Cancer Research
13. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
    Dafydd Gwyn Bebb, Shantanu Otto Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet E. Feilotter, Aaron Richard Hansen, Martin D. Hyrcza, Monika Karolina Krzyzanowska et al. · 2021 · Current Oncology
14. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
    Clare Keddy, Pushkar Shinde, Kristen L. Jones, Stefanie Kaech, Romel Somwar, Ujwal P. Shinde, Monika Ashok Davare · 2021 · Molecular Cancer Therapeutics
15. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study
    Li, Wei, Xiong, Anwen, Yang, Nong, Fan, Huijie, Yu, Qitao, Zhao, Yanqiu, Wang, Yongsheng, Meng, Xue, Wu, Jingxun, Wang, Ziping et al. · 2024 · Journal of Clinical Oncology
16. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
    Sunil Kumar Joshi, Kristin Qian, William H. Bisson, Kevin Watanabe‐Smith, Ariane Huang, Daniel Bottomly, Elie A. Traer, Jeffrey W Tyner, Shannon K. McWeeney, Monika Ashok Davare et al. · 2020 · Blood
17. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review
    Hala Bakr El‐Nassan, Mustafa A. Al-Qadhi · 2023 · European Journal of Medicinal Chemistry
18. Revisiting NTRKs as an emerging oncogene in hematological malignancies
    Sunil Kumar Joshi, Monika Ashok Davare, Brian J. Druker, Cristina E. Tognon · 2019 · Leukemia
19. A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
    Yue Lu, Zhenzhen Fan, Sujie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang et al. · 2021 · EMBO Molecular Medicine
20. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
    Andreas Papapetropoulos, Stavros Topouzis, S P H Alexander, Miriam Margherita Cortese-Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri, Hemal H. Patel et al. · 2024 · British Journal of Pharmacology
21. Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
    Matthew L. Hemming, Michael Jason Nathenson, Jia‐Ren Lin, Shaolin Mei, Ziming Du, Karan Malik, Adrián Mariño‐Enríquez, Jyothi Priya Jagannathan, Peter Karl Sorger, Monica M. Bertagnolli et al. · 2020 · JCO Precision Oncology
22. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
    Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan Daniel Wasserman et al. · 2021 · Current Oncology
23. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
    Anna Michelotti, Marco de Scordilli, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz · 2022 · International Journal of Molecular Sciences
24. Advances and future directions in ROS1 fusion-positive lung cancer
    Boulanger, Mary C, Schneider, Jaime L, Lin, Jessica J · 2024 · The Oncologist
25. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer
    José Luis Leal, Geoffrey David Peters, Marcin Szaumkessel, Trishe Y.-M. Leong, Khashayar Asadi, Gareth Rivalland, Hongdo Do, Clare Senko, Paul L R Mitchell, Chai Zi Quing et al. · 2020 · Lung Cancer
26. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib
    Shuang Xiang, Xiaoyun Lu · 2023 · Acta Pharmaceutica Sinica B
27. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
    Kartik Sehgal, Andrew J. Piper‐Vallillo, Hollis Viray, Adeel M. Khan, Deepa Rangachari, Daniel Botelho Costa · 2020 · Precision Cancer Medicine
28. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019
    Justin J. Bailey, Carolin Jaworski, Donovan Tung, Carmen Wängler, Björn Wängler, Ralf Schirrmacher · 2020 · Expert Opinion on Therapeutic Patents
29. Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
    Debasis Das, Jingbing Wang, Jian Hong · 2021 · ChemMedChem
30. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
    Matthew K. Stein, Oluchukwu Oluoha, Kruti Patel, Ari M. Vanderwalde · 2021 · Journal of Personalized Medicine
31. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
    Shivaani Kummar, Lin Shen, David S. Hong, Ray McDermott, Vicki Leigh Keedy, Michela Casanova, George D. Demetri, Afshin Dowlati, Soledad Gallego, Ulrik Lassen et al. · 2023 · Cancer
32. Repotrectinib: First Approval
    Sohita Dhillon · 2024 · Drugs
33. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
    Sun‐Young Han · 2021 · Pharmaceuticals
34. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
    Ezra Y. Rosen, Alison M. Schram, Robert J. Young, Mark Schreyer, Jaclyn Frances Hechtman, Catherine A. Shu, Nora C. Ku, David Michael Hyman, Alexander Edward Dela Cruz Drilon · 2019 · JCO Precision Oncology
35. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
    Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S. Bowman, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina et al. · 2020 · Clinical Cancer Research
36. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
    Ling Peng, Dafeng Lu, Yang Xia, Shaodong Hong, Giovanni Selvaggi, Justin Stebbing, Yilan Sun, Fei Liang · 2021 · Frontiers in Oncology
37. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
    Vivek Subbiah, Mohamed Alaa Gouda, Julian Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven I. Sherman, Maria E. Cabanillas, Mimi I-Nan Hu, Luz E. Castellanos, Behrang Amini et al. · 2024 · npj Precision Oncology
38. Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
    Defa Wu, Qian Sun, Haolin Tang, Huan Xiao, Jiaxiang Luo, Liang Ouyang, Qiu Sun · 2024 · Drug Resistance Updates
39. Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
    Diana Cervantes-Madrid, Joanna Szydzik, Dan Emil Lind, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth Helen Palmer, Bengt Hallberg · 2019 · Scientific Reports
40. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors
    Siming Liu, Ying Jiang, Ruohong Yan, Zhonghuang Li, Shanhe Wan, Tingting Zhang, Xiaoyun Wu, Ju Hou, Zhengguang Zhu, Yuanxin Tian et al. · 2019 · European Journal of Medicinal Chemistry
41. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
    Diego Erich Kauffmann-Guerrero, Kathrin Kahnert, Rudolf Maria Huber · 2020 · Drugs
42. The promise of TRK inhibitors in pediatric cancers with NTRK fusions
    Emily R. Blauel, Theodore Willis Laetsch · 2022 · Cancer Genetics
43. Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
    Alberto Puccini, Andreas Seeber, Martin D. Berger · 2022 · Cancers
44. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F])
    Sai‐Hong Ignatius Ou, Garo Greg Hagopian, Shannon S. Zhang, Misako Nagasaka · 2023 · Journal of Thoracic Oncology
45. FDA‐approved drugs featuring macrocycles or medium‐sized rings
    Youlong Du, Anas Semghouli, Qian Wang, Haibo Mei, Lóránd Kiss, Daniel Baecker, Vadim A. Soloshonok, Jianlin Han · 2025 · Archiv der Pharmazie
46. The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
    Haixia Qin, Manish Ramesh Patel · 2022 · International Journal of Molecular Sciences
47. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers
    David Stephen Shulman, Steven G. DuBois · 2020 · Pediatric Drugs
48. Targeting TRK: A fast-tracked application of precision oncology and future directions
    Arsenije Kojadinovic, Bahar Laderian, Prabhjot Singh Mundi · 2021 · Critical Reviews in Oncology/Hematology
49. Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
    Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain Jonathan Gelibter · 2022 · Drugs in Context
50. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
    Kajetan Kiełbowski, Justyna Żychowska, Rafał Becht · 2023 · Frontiers in Pharmacology
51. Importance of ROS1 fene fusions in non-small cell lung cancer
    Meri Muminovic, Carlos Rodrigo Carracedo Uribe, Andrés M. Alvarez-Pinzon, Khine Swe Shan, Luis Estuardo Raez · 2023 · Cancer Drug Resistance
52. Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
    Maria El Hage, Zhaoran Su, Michael Linnebacher · 2025 · Cancers
53. RET kinase alterations in targeted cancer therapy
    Xuan Liu, Xueqing Hu, Tao Shen, Qi Li, Blaine H. M. Mooers, Jie Wu · 2020 · Cancer Drug Resistance
54. Targeted Therapy for Non-Small Cell Lung Cancer
    Zorawar Singh Noor, Amy Lauren Cummings, McKenna M. Johnson, Marshall L. Spiegel, Jonathan Wade Goldman · 2020 · Seminars in Respiratory and Critical Care Medicine
55. Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
    Katarzyna Magdalena Stencel, Izabela Chmielewska, Janusz Milanowski, Rodryg Ramlau · 2021 · Cancers
56. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
    Dandan Xu, Deqiao Sun, Wei Wang, Xia Peng, Zhengsheng Zhan, Yinchun Ji, Yanyan Shen, Meiyu Geng, Jing Ai, Wenhu Duan · 2021 · European Journal of Medicinal Chemistry
57. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China
    Lijuan Yin, Changle Shi, Xin Zhi He, Qiu Yan, Huijiao Chen, Min Chen, Zhang Zhang, Yihua Chen, Yanyan Zhou, Hongying Zhang · 2022 · Pathology
58. Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
    Benjamin Besse, Jessica J. Lin, Lyudmila A. Bazhenova, Koichi Goto, Adrianus Johannes De Langen, Dong‐Wan Kim, Jürgen Wolf, Christoph Springfeld, Sanjay Popat, Wan‐Teck Lim et al. · 2026 · Nature Medicine
59. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology
    Kristoffer Staal Rohrberg, Ulrik Lassen · 2021 · Drugs
60. NTRK fusions in colorectal cancer: clinical meaning and future perspective
    Margherita Ratti, Giulia Grizzi, Rodolfo Passalacqua, Andrea Lampis, Fabrizio Cereatti, Roberto Grassia, Jens Claus Hahne · 2021 · Expert Opinion on Therapeutic Targets
61. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer
    Josh John Carlson · 2022 · The American Journal of Managed Care
62. Oncogenic fusions: Targeting NTRK
    Garo Greg Hagopian, Misako Nagasaka · 2023 · Critical Reviews in Oncology/Hematology
63. NTRK gene fusion testing and management in lung cancer
    Matteo Repetto, Marina Chiara Garassino, Herbert Ho-Fung Loong, Fernando López‐Ríos, Tony S.K. Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R. Rudzinski, Alexander Edward Dela Cruz Drilon et al. · 2024 · Cancer Treatment Reviews
64. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
    Yi‐Ru Bai, Dong‐Jie Seng, Ying Cao Xu, Yaodong Zhang, Wenjuan Zhou, Yang-Yang Jia, Jian Zheng Song, Zhangxu He, Hong‐Min Liu, Shuo Yuan · 2024 · European Journal of Medicinal Chemistry
65. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
    Sun Min Lim, Stefanie S. Schalm, Eun Ji Lee, Sewon Park, Chiara Conti, Yves A. Millet, Rich Woessner, Zhuo Zhang, Luz E. Tavera-Mendoza, Faith Stevison et al. · 2024 · Therapeutic Advances in Medical Oncology
66. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
    Marissa Lam, Caroline Lum, Sarah Latham, Sam Tipping Smith, Hans Prenen, Eva Segelov · 2020 · Cancer Management and Research
67. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
    Simon Strohmeier, Iva Brčić, Helmut Popper, Bernadette Liegl‐Atzwanger, Jörg Lindenmann, Luka Brčić · 2021 · Scientific Reports
68. NTRK fusions in thyroid cancer: Pathology and clinical aspects
    Yanhui Ma, Qi Zhang, Kexin Zhang, Yunzi liang, Fangbing Ren, Jingwen Zhang, Chengxia Kan, Fang Han, Xiaodong Sun · 2023 · Critical Reviews in Oncology/Hematology
69. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers
    Anna F. Farago, George D. Demetri · 2020 · Future Oncology
70. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants
    Beilei Wang, Wentao Zhang, Xuesong Liu, Fengming Zou, Jun‐Jie Wang, Qingwang Liu, Aoli Wang, Zhenquan Hu, Yongfei Chen, Shuang Qi et al. · 2020 · European Journal of Medicinal Chemistry
71. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
    Tao Yang, Mengshi Hu, Yong Xia Chen, Mingli Xiang, Minghai Tang, Wenyan Qi, Mingsong Shi, Jun He, Xue Yuan, Chufeng Zhang et al. · 2020 · Journal of Medicinal Chemistry
72. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
    Paul Beinhoff, Lavannya Sabharwal, Vindhya Udhane, Cristina Maranto, Peter S. LaViolette, Kenneth M. Jacobsohn, Susan Tsai, Kenneth A. Iczkowski, Liang Wang, William Adrian Hall et al. · 2021 · Cancers
73. Current therapy and development of therapeutic agents for lung cancer
    Zilai Wang, Jiyeon Kim, Pin Zhang, Jazmin Galván Achi, Yuwei Jiang, Lijun Rong · 2022 · Cell Insight
74. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics
    Matti L. Gild, Martyn Bullock, Venessa Tsang, Roderick John Clifton-Bligh, Bruce G. Robinson, Lori J. Wirth · 2023 · Thyroid
75. New perspectives for targeting therapy in ALK-positive human cancers
    Simin Zhao, Jian Li, Qingxin Xia, Kangdong Liu, Zigang Dong · 2023 · Oncogene
76. Salivary gland carcinoma: Towards a more personalised approach
    Layal Rached, Khalil Saleh, Odile Casiraghi, Caroline Even · 2024 · Cancer Treatment Reviews
77. Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
    Nicholas Giustini, Ah‐Reum Jeong, James A. Buturla, Lyudmila A. Bazhenova · 2020 · Clinics in Chest Medicine
78. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
    Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda R. Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Liyamali Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer et al. · 2024 · British Journal of Cancer
79. NTRK-Fusions – A new kid on the block
    Bruno Märkl, Klaus Hirschbühl, Christine Dhillon · 2019 · Pathology - Research and Practice
80. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
    Francesco Facchinetti, Luc Friboulet · 2019 · Lung Cancer Targets and Therapy
81. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
    Pilar Garrido, Raquel Hladun, Enrique de Álava, Rosa Maria Alvarez, Francisco José Bautista, Fernando López‐Ríos, Rámón Colomer, Federico Rojo · 2021 · Clinical & Translational Oncology
82. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II
    Javier Martínez‐Trufero, Josefina Cruz Jurado, Carmen Nieves Hernández-León, Raquel Correa, José Manuel Asencio, Daniel Bernabéu, Rosa Maria Alvarez, Nadia Hindi, Cristina Mata, Gloria Marquina et al. · 2021 · Cancer Treatment Reviews
83. Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours
    Yuehua Li, Chengjiang Wei, Wei Wang, Qingfeng Li, Zhichao Wang · 2022 · The Journal of Pathology Clinical Research
84. New developments in targeted therapy for metastatic colorectal cancer
    Ambrose H. N. Wong, Brigette B.Y. Ma, Rashid Nok-Shun Lui · 2023 · Therapeutic Advances in Medical Oncology
85. A novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation
    Baijiao An, Wenyan Nie, Jinhui Hu, Yangyang Fan, Haoran Nie, Mengxuan Wang, Yaxuan Zhao, Han Yao, Yuanyuan Ren, Chuanchuan Zhang et al. · 2023 · Cell Death and Disease
86. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
    Mu‐Chun Li, Wen‐Hsing Lin, Peichen Wang, Yu‐Chieh Su, Pei‐Yi Chen, Chu-Min Fan, Ching-Ping Chen, Chen‐Lung Huang, Chun-Hsien Chiu, Ling Chang et al. · 2021 · European Journal of Medicinal Chemistry
87. Therapeutic Options in Neuro-Oncology
    Mariana Gomes Afonso, María Alexandra Brito · 2022 · International Journal of Molecular Sciences
88. Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
    Antoine Desîlets, Matteo Repetto, Soo‐Ryum Yang, Alexander Drilon · 2025 · Cancer
89. New approaches for patients with advanced radioiodine-refractory thyroid cancer
    Fabián Pitoia, Fernando Jerkovich, Pierpaolo Trimboli, Anabella Smulever · 2022 · World Journal of Clinical Oncology
90. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance
    Yi Gong, Fengxu Wu, Mingshu Wang, Hong-Chuang Xu, Linsheng Zhuo, Guang‐Fu Yang, Wei Huang · 2022 · European Journal of Medicinal Chemistry
91. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer
    the Israel Lung Cancer Group, Elizabeth Dudnik, Abed Agbarya, R. Grinberg, Arnold Cyjon, Jair Bar, Mor Tal Moskovitz, Nir Peled · 2020 · Clinical & Translational Oncology
92. The present and future of precision oncology and tumor-agnostic therapeutic approaches
    Nakul M. Shah, Funda Meric‐Bernstam · 2025 · The Oncologist
93. ATP-competitive inhibitors for cancer treatment – kinases and the world beyond
    Ana Jug, Janez Ilaš · 2025 · RSC Medicinal Chemistry
94. Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis
    Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda et al. · 2019 · Journal of Thoracic Disease
95. NTRK point mutations and their functional consequences
    Corey Rogers, Jennifer J. D. Morrissette, Robyn T. Sussman · 2021 · Cancer Genetics
96. Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
    Baku Acharya, Debasmita Saha, Daniel Armstrong, Baha’a Jabali, Maha Hanafi, Alan Herrera-Rueda, Naga Rajiv Lakkaniga, Brendan Frett · 2023 · RSC Medicinal Chemistry
97. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
    Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum et al. · 2024 · Clinical Cancer Research
98. TRK Inhibitors in Non-Small Cell Lung Cancer
    Guilherme Harada, Aline Bobato Lara Gongora, Cesar Martins da Costa, Fernando Costa Santini · 2020 · Current Treatment Options in Oncology
99. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
    C. Xu, Lu Si, Wenxian Wang, Ziming Li, Zhengbo Song, Qian Wang, Aijun Liu, Jinpu Yu, Wenfeng Fang, Wen‐Zhao Zhong et al. · 2022 · Thoracic Cancer
100. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy
     Shuang Xiang, Jie Wang, Huisi Huang, Zuqin Wang, Xiaojuan Song, Yang Zhou, Feng Jin, Xun Jun He, Zhimin Zhang, Zhengchao Tu et al. · 2022 · European Journal of Medicinal Chemistry